The CTLA-4 receptor is a critical inhibitory regulator of T cell proliferation and effector function. However, the mechanisms through which CTLA-4 modulates the activation of T cells remain uncertain. Initial studies, using activated human T cells, have suggested that CTLA-4 crosslinking may induce apoptosis. However, more recent experiments have demonstrated that crosslinking of the CTLA-4 receptor on the surface of resting murine T cells blocks cell cycle progression without inducing apoptosis. Here we provide evidence that CTLA-4 crosslinking on the surface of activated murine CD4 ؉ T lymphocytes leads to death of a substantial fraction of the cells whereas in resting CD4 ؉ T cells the same stimulation conditions induce cell cycle arrest without apoptosis. Cell death induced by CTLA-4 stimulation occurs independently of Fas and therefore may involve a novel pathway. CTLA-4-mediated apoptosis may be a means of terminating the function of previously stimulated T cells. Exploitation of this mechanism also may provide a therapeutic strategy to eliminate alloreactive or autoreactive T cells.
T lymphocytes, which are induced to proliferate and to express their effector functions. As a consequence of the expansion of antigen-specific T cells, cellular and͞or humoral immune reactions emerge that, in most cases, lead to the elimination of cells expressing foreign antigens. Eventually, the immune response is self-limited and wanes with time after antigen exposure (1) .
Studies carried out during the past several years have established that the molecules of the B7 family, B7-1 (CD80) (2, 3) and B7-2 (CD86) (4) (5) (6) , play an important role in the regulation of immune responses. These proteins control immune responses through their capacity to positively or negatively influence the activation of CD4 ϩ T cells that are being stimulated through their T cell antigen receptor (TCR) (7, 8) .
B7-1 and B7-2 each bind to two receptors on T cells, termed CD28 and CTLA-4 (CD152) (9) (10) (11) . The CD28 and CTLA-4 proteins share amino acid sequences and have similar overall structure, but appear to serve different functions: principally, crosslinking of the CD28 receptor enhances (12) and crosslinking of the CTLA-4 receptor inhibits (13) T cell activation. In addition, CD28 and CTLA-4 have different characteristics of ligand binding, with CTLA-4 having a higher affinity for B7 molecules than CD28 (14) .
The different functions of the CD28 and CTLA-4 receptors are illustrated most clearly by the phenotype of the respective knockout mice. CD28-deficient mice are immunodeficient when studied in a series of assays (15, 16) . By contrast, CTLA-4-deficient mice are characterized by a rampant lymphoproliferative disorder that leads to death by 3-4 weeks of age (17, 18) . Available evidence suggests that this breakdown of lymphoid homeostasis in CTLA-4-deficient mice results from a failure in peripheral tolerance (19) .
The expression of CTLA-4 is tightly controlled. Resting T cells express very low levels of CTLA-4. However, CTLA-4 expression is up-regulated strongly upon activation of the T cell. Based on its pattern of expression, it was thought originally that CTLA-4 might function exclusively in activated T cells. More recently, a new model has been proposed that suggests that CTLA-4 may be functional on resting as well as on activated T cells (19) . According to this model, presentation of antigenic peptide by an antigenpresenting cell that expresses low levels of B7 fails to stimulate resting T cells, because of inhibition by CTLA-4. CTLA-4-mediated inhibition can only be overcome if the resting T cell encounters an antigen-presenting cell that expresses high levels of B7 molecules, effectively resulting in CD28 stimulation. However, once the T cell has become fully activated it expresses high levels of CTLA-4, which may be able to override signals transduced by CD28 even if the T cell encounters an antigen-presenting cell that expresses high levels of antigen and B7 molecules (20) . Therefore, CTLA-4 may serve two functions: on resting T cells it may serve to attenuate signals mediated by the TCR and CD28 and thus contribute to peripheral tolerance. By contrast, on activated T cells CTLA-4 may serve to terminate T cell activation.
It is currently unresolved through which mechanisms CTLA-4 inhibits the activation of CD4 ϩ T cells. Initial studies, using activated human T cells, suggested that CTLA-4 crosslinking may induce apoptosis. Cell death was postulated to occur through a novel CTLA-4 counter-receptor, distinct from B7-1 and B7-2 (21) . By contrast, more recent studies have demonstrated that signaling through the CTLA-4 receptor can block the proliferative response of resting murine T cells to a synergistic combination of anti-CD3 and anti-CD28 mAbs by inhibiting the production of IL-2 and thus eliciting an arrest in cell cycle progression from G 0 ͞G 1 (13, (22) (23) (24) (25) .
In the current study we have examined the effects of CTLA-4 crosslinking on activated murine CD4 ϩ T cells. Our results indicate that crosslinking of CTLA-4 by a biotinylated anti-CTLA-4 mAb and avidin can induce apoptosis of previously stimulated T cells; in contrast to its effect on activated T cells, crosslinking of CTLA-4 on the surface of freshly isolated T cells leads to cell cycle arrest in G 0 ͞G 1 without apoptosis. Cell death induced by CTLA-4 crosslinking occurs in a Fas-independent fashion. conjugated hamster anti-TNP mAb (clone G235-2356; PharMingen); and unconjugated hamster anti-mouse-Fas (clone Jo2; PharMingen). The anti-CD28 mAb-secreting hybridoma 37.51 (26, 27) was kindly provided by Jim Allison, University of California at Berkeley. The anti-I-A b,d,q , anti-IE d,k hybridoma M5͞114 (28) and the anti-CD8.2 hybridoma ADH4 (29) were obtained from the American Type Culture Collection (Manassas, VA). The anti-CTLA-4 mAb-secreting hybridoma UC10-4F10-11 (13) was kindly provided by Jeff Bluestone, University of Chicago. Anti-CD28 and anti-CTLA-4 mAbs were affinity-purified from mouse ascites. Purified anti-CTLA-4 mAb was biotinylated with sulfo-NHSbiotin (Pierce), according to the manufacturer's instructions.
Lymphocyte Purification and Bulk Cell Culture. Mice were killed by CO 2 narcosis followed by cervical dislocation. Singlecell suspensions were prepared from harvested spleens. Erythrocytes were depleted by incubating the cells with buffer containing 17 mM Tris͞140 mM NH 4 Cl, pH 7.65 on ice for 5 min. The cells were washed and resuspended in complete culture medium (RPCCM). RPCCM consisted of RPMI 1640 medium (GIBCO͞BRL), supplemented with 10% FCS͞4 mM L-glutamine (GIBCO͞BRL)͞10 mM Hepes (GIBCO͞BRL)͞ nonessential amino acids (Sigma)͞100 units͞ml penicillin G (GIBCO͞BRL)͞100 g͞ml streptomycin sulfate (GIBCO͞ BRL)͞250 ng͞ml amphotericin B (GIBCO͞BRL)͞50 M 2-mercaptoethanol (Sigma) (30) . In most experiments, splenocytes were stimulated with 2.5 g͞ml Con A (Sigma) at a density of 10 6 cells per ml. After 3 days the cells were harvested and CD4 ϩ cells were purified as previously described by negative depletion (30) . Briefly, the splenocytes were incubated with hybridoma supernatants of M5͞114 (anti-mouse
) and ADH4 (anti-mouse CD8.2) on ice for 30 min, washed and incubated with a suspension of goat anti-mouse IgG magnetic beads (PerSeptive Biosystems) according to the manufacturer's instructions. After removal of bead-bound cells by a magnet, the procedure was repeated once with the remaining cells. This procedure typically results in Ͼ98% pure CD4 ϩ cells as evidenced by FACS analysis (ref. 30 ; data not shown). CD4 ϩ T cells were either subjected directly to cell cycle analysis or restimulated in a secondary culture. For experiments with freshly isolated CD4 ϩ T cells, erythrocytedepleted splenocytes were subjected immediately to negative depletion as outlined above.
Proliferation Assays. Microcultures (200 l) were set up in triplicate as described (30) , except that RPCCM contained biotinfree RPMI 1640 medium (GIBCO͞BRL) instead of regular RPMI 1640. Where indicated, culture media were supplemented with one or several of the following additives: Con A, anti-CD28 mAb 37.51, biotinylated anti-CTLA-4 mAb UC10-4F10-11, and avidin-D (Vector Laboratories). Where indicated, avidin was presaturated with biotin by incubation for 1 h at 37°C with at 10-fold molar excess of biotin (Sigma). The precise culture constituents and incubation periods are described in the respective figure legends. All cultures were pulsed with 1 Ci (37 kBq) of [ 3 H]thymidine per well for the last 6 h of the 48-h incubation period to assay for T cell proliferation.
Restimulation of Activated CD4 ؉ T Cells for Cell Cycle Analysis. Spleen cells were stimulated with Con A (2.5 g͞ml) for 72 h. CD4 ϩ T cells were purified as described above and recultured in 24-well plates at a cell density of 5 ϫ 10 5 per well, in 1 ml of RPCCM medium containing biotin-free RPMI 1640 medium (GIBCO͞BRL) instead of regular RPMI 1640. Where indicated, culture media were supplemented with one or several of the following additives: Con A (2.5 g͞ml), anti-CD28 mAb 37.51 (2 g͞ml), anti-Fas mAb Jo2 (5 g͞ml), biotinylated anti-CTLA-4 mAb UC10-4F10-11 (10 g͞ml), and avidin-D (Vector Laboratories) (20 g͞ml). Where indicated in the figure legends, avidin was presaturated with biotin by incubation with a 10-fold molar excess of biotin (Sigma) for 1 h at 37°C. Eighteen to 24 h after initiation of the culture, T cells were harvested for cell cycle analysis.
Flow Cytometric Analysis of Cell Surface Antigens. To determine cell surface expression of CTLA-4, Fas, and other proteins, CD4 ϩ T cells were analyzed by direct immunofluorescence and flow cytometry. Briefly, 10 6 cells were suspended in 50 l RPMI 1640 (5% FCS͞Hepes͞L-glutamine) containing 10 g͞ml of the respective staining antibody. After a 40-min incubation on ice, the cells were washed twice with 500 l of the same medium and once with PBS containing 1% BSA (Sigma). Cells were resuspended in PBS and analyzed on a Coulter Epics XL-MCL flow cytometer.
Cell Cycle Analysis. Cell cycle analysis was carried out as previously described (31) . Briefly, purified CD4 ϩ cells, prepared as described above, were harvested and washed once in 1 ml PBS. Cells were resuspended in 0.1% Nonidet P-40͞0.1% sodium citrate including 50 g͞ml propidium iodide (Sigma) and analyzed within 24 h by flow cytometry using a Coulter Epics XL-MCL instrument.
RESULTS
The objective of our study was to examine the functional effect of CTLA-4 crosslinking on the surface of prestimulated T lymphocytes. Our basic experimental approach is outlined in Fig. 1 . Splenocytes from BALB͞c or C57BL͞6 mice were incubated with Con A for 3 days and CD4 ϩ cells were subsequently purified from this population. The flow cytometry profiles in the lower graphs of Fig. 1 illustrate that, as expected, freshly isolated splenic CD4 ϩ cells express very low amounts of CTLA-4. By contrast, after Con A stimulation in the presence of endogenous antigen-presenting cells, CTLA-4 becomes readily up-regulated (13) . These preactivated CD4 ϩ cells subsequently were restimulated under varying conditions and subjected to cell cycle analysis by staining nuclear DNA with propidium iodide and analyzing the amount of incorporated dye by flow cytometry. Typical profiles are shown in Fig.  1 . As expected, nearly all resting CD4 ϩ cells were found to be in the region corresponding to the G 0 ͞G 1 phases of the cell cycle. After stimulation for 72 h in the presence of antigenpresenting cells, a significant fraction of the CD4 ϩ cells, typically 30-50%, were in the G 2 ͞S phases of the cell cycle, indicating that they had been activated substantially. The appearance of cells in the G 2 ͞S phases depended on the simultaneous stimulation of resting CD4 ϩ T cells by Con A and a costimulatory signal (antigen-presenting cells, anti-CD28 mAb) (data not shown; see also refs. 23 and 24).
Importantly, this requirement for a costimulatory signal was maintained when purified, activated CD4 ϩ T cells were restimulated in a secondary culture (Fig. 1 Right) . When the T cells were restimulated with Con A alone or recultured with medium alone, only a small fraction of cells remained in the G 2 ͞S region after 24 h. Moreover, a substantial fraction of the cells had an apoptotic phenotype as evidenced by a subdiploid DNA content. By contrast, restimulation of CD4 ϩ T cells with Con A in the presence of anti-CD28 mAb kept a significant fraction of the cells in the G 2 ͞S phases, with the remaining cells mostly in the G 1 phase and a small fraction (Ͻ15%) in the subdiploid region.
The requirement for a costimulatory signal in restimulation cultures also was observed when the incorporation of [ 3 H]thymidine was measured as an indicator of T cell proliferation. Restimulation of purified CD4 ϩ T cells with Con A in the absence of a costimulatory signal did not lead to cell proliferation. By contrast, significant incorporation of [ 3 H]thymidine was observed when anti-CD28 mAb was added to the culture (Fig. 2) .
CTLA-4 Triggering Induces Apoptosis in Prestimulated CD4 ؉ T Lymphocytes. We subsequently examined the effects of CTLA-4 stimulation on the surface of preactivated CD4 ϩ T cells. To achieve crosslinking of the CTLA-4 receptor, we incubated preactivated CD4 ϩ cells first with biotinylated anti-CTLA-4 mAb and subsequently with avidin. We chose this experimental approach because it has been used in other experimental systems to induce effective crosslinking of target molecules (e.g., ref. 32).
Crosslinking of CTLA-4 on the surface of preactivated CD4 ϩ T cells abrogated the proliferation normally induced in secondary cultures by a combination of Con A and anti-CD28 mAb (Fig. 2) . The inhibitory effect of CTLA-4 crosslinking was specific, because the addition of either biotinylated anti-CTLA-4 mAb or avidin alone did not inhibit T cell proliferation (Fig. 2) . T cell proliferation also was not inhibited when avidin was presaturated with an excess amount (10-fold molar excess over avidin) of free biotin before addition to the culture (Fig. 2) . Next we examined whether CTLA-4 crosslinking had an effect on the propidium iodide staining profiles of purified activated CD4 ϩ T cells that were restimulated with Con A and anti-CD28 mAb. Consistent with its observed effect on T cell proliferation, crosslinking of CTLA-4 lead to a dramatic reduction of cells in S͞G 2 (Fig. 3) . Moreover, a substantial increase in the subdiploid population was observed, indicating that cells had died as a consequence of CTLA-4 engagement (Fig. 3) . As in the case of the proliferative responses, the effect of CTLA-4 crosslinking on the cell cycle distribution pattern was specific, because the addition of either biotinylated anti-CTLA-4 mAb or avidin alone did not inhibit the CTLA-4-induced increase in the number of T cells with subdiploid DNA content. Increased cell death also was not observed when avidin was presaturated with an excess amount of free biotin before addition to the culture (Fig. 3) or when the T cells were incubated with an irrelevant biotinylated antibody and avidin (data not shown). The increased percentage of cells with subdiploid DNA content in cultures receiving CTLA-4 crosslinking was a result of an increase in the number of apoptotic cells because, at time of analysis (18 and 24 h), the total number of cells in control T cell cultures was only marginally different from cultures with CTLA-4 crosslinking. In 17 independent experiments, the differences in cell numbers were within a range of 25%, with only 3 experiments exceeding 15% difference. This result rules out a trivial explanation for our data, namely that all cultures contained equal numbers of apoptotic cells but such apoptotic T cells were diluted out in control groups through expansion of the remaining T cell population. It is also noteworthy that the CTLA-4-induced increase in the number of apoptotic cells cannot be the result of mere cell cycle arrest, because aphidocolin, a chemical known to induce G 1 arrest, did not significantly enhance the number of apoptotic cells at concentrations that effectively inhibited cell cycle progression (data not shown). Although there was quantitative variation between different experiments, CTLA-4-induced cell death of preactivated CD4 ϩ T cells was observed consistently: in eight independent experiments, CTLA-4 crosslinking led to a 3.5 Ϯ 1.4 We subsequently compared directly the effects of CTLA-4 crosslinking on preactivated versus resting T cells. To carry out this comparison we had to modify the experimental approach described above, because crosslinking of CTLA-4 in freshly isolated T cells completely blocks proliferation, resulting in much diminished cell numbers at the end of the incubation period. To circumvent this problem we adopted the experimental approach developed by Krummel and Allison (23) and analyzed the cells for a fixed time period at a constant flow rate. The result of a typical experiment is shown in Fig. 4 . Whereas crosslinking of CTLA-4 on the surface of preactivated T cells led to apoptosis, as shown above, crosslinking on the surface of freshly isolated CD4 ϩ T cells inhibited cell cycle progression from G 0 ͞G 1 without cell death (Fig. 4) . This latter result is consistent with the observations of the Allison and Bluestone laboratories (13, (22) (23) (24) . Activated T Cells from lpr Mice Can Be Killed by CTLA-4 Crosslinking. To further investigate this point, we examined whether CTLA-4 crosslinking could kill activated T cells that were genetically deficient in Fas expression. For this purpose, we generated activated CD4 ϩ T cells from young C57BL͞6-lpr͞lpr mice as outlined above for wild-type T cells. Preactivated CD4 ϩ cells from both mice expressed comparable amounts of CTLA-4 as assessed by flow cytometry (data not shown). As shown in Fig. 6 Left, crosslinking of CTLA-4 on the surface of activated lpr T cells led to cell death, at a frequency not lower than that observed for wild-type T cells that were analyzed in parallel (Fig. 6 Right) . This result formally demonstrates that CTLA-4 crosslinking can kill activated CD4 ϩ T cells in a Fas-independent fashion. crosslinking. BALB͞c splenocytes were stimulated for 3 days with Con A (2.5 g͞ml) in RPCCM. After 3 days the cells were harvested and CD4 ϩ cells were purified as described in Materials and Methods. Purified CD4 ϩ cell blasts were recultured for 24 h in biotin-free RPCCM medium in 24-well plates (1 ml) at a density of 5 ϫ 10 5 per well. Where indicated, Con A (2.5 g͞ml), anti CD28 mAb 37.51 (2 g͞ml), biotinylated anti-CTLA-4 mAb UC10-4F10-11 (10 g͞ml), and͞or avidin (20 g͞ml) were added to the cultures. In one experimental group, avidin was added that had been presaturated with free biotin as detailed in Materials and Methods. At the end of the incubation period the cells were harvested and washed once in PBS. Cells were resuspended in 0.1% Nonidet P-40, 0.1% sodium citrate, and 50 g͞ml propidium iodide and analyzed by flow cytometry. Events were analyzed for propidium iodide fluorescence and markers were set corresponding to subdiploid, G0͞G1, and S͞G2 quantities. Above each of the marked regions, events are indicated as a percentage of the total number of events (10,000 ϭ 100%).
DISCUSSION
Crosslinking of the CTLA-4 receptor by mAb on the surface of resting (23, 24) and activated (this report) murine T cells can inhibit T cell proliferation. What remains uncertain is how CTLA-4 mediates this function. Results from studies carried out by the Allison and Bluestone laboratories have established that CTLA-4 crosslinking on the surface of freshly isolated T cells leads to an arrest in cell cycle progression from G 0 ͞G 1 without evidence of T cell death (23, 24) . In this study, we provide evidence that CTLA-4 crosslinking on the surface of prestimulated murine T cells leads to the death of a substantial fraction of the T cells. By contrast, CTLA-4 crosslinking on the surface of freshly isolated T cells leads to cell cycle arrest. Therefore, the cellular responses to CTLA-4 crosslinking may be more complex than previously appreciated.
There are several possibilities to explain the differential effects of CTLA-4 crosslinking on freshly isolated versus activated T cells. (i) It is conceivable that CTLA-4 induces different biochemical signals in resting versus activated cells. Such differential receptor signaling certainly is not without precedence: It is well known that the signaling capacity of some receptors is influenced by the activation states of the cell in which it is expressed. Typically, such changes in receptor signaling are due to either modifications of the receptor itself (e.g., receptor phosphorylation) or to alterations of the cytosolic milieu in which the receptor operates. It is likely that the cytoplasmic domain of CTLA-4 is altered (e.g., phosphorylated) upon T cell stimulation, although TCR-or CD28-induced alterations have yet to be documented (20) . Moreover, there are dramatic changes in the amounts and composition of cytosolic signaling modules that occur upon T cell stimulation (36) and that could account for differential signaling effects of the CTLA-4 receptor. (ii) It is possible that CTLA-4 crosslinking elicits the same biochemical signals in resting and activated T cells. According to this model, the principal effect of CTLA-4 stimulation would be to block interleukin 2 (IL-2) production; however, this block would have different consequences depending on the state of the T cell. In the case of a resting T cell, CTLA-4 stimulation would lead to arrest in cell cycle progression because progression depends on growth factor production. In the case of an activated T cell, cell death may be a consequence of depriving an activated, IL-2-dependent T cell of its growth factor. (iii) Finally, the thresholds for arresting versus apoptotic signals might be different. Specifically, it is conceivable that the induction of apoptosis might require levels of CTLA-4 that are present only on the surface of activated T cells. Currently, we cannot distinguish between these possibilities.
The results of experiments with anti-Fas antibodies as well as those using T cells from lpr mice indicate that CTLA-4-induced cell death proceeds in a Fas-independent fashion. This finding is not without precedence because receptors other than Fas have been described recently that can mediate killing of activated T cells (37) (38) (39) .
Finally, studies of costimulatory pathways have enhanced our knowledge of immunologic diseases and opened up new possibilities for prophylactic and therapeutic intervention (8) . In this context it is noteworthy that Colucci et al. (40) have mapped a gene responsible for apoptosis resistance of lymphocytes from nonobese diabetic mice to within 20 cM of the Ctla-4 locus; these investigators also found that CTLA-4 expression was defective in FIG. 4 . CTLA-4 crosslinking on freshly isolated CD4 ϩ T cells inhibits cell cycle progression without apoptosis induction. Resting CD4 ϩ cells and CD4 ϩ blasts were prepared as described in Materials and Methods. Purified resting CD4 ϩ cells were cultured for 72 h and preactivated CD4 ϩ cells were recultured for 24 h in biotin-free RPCCM medium containing Con A (2.5 g͞ml), anti-CD28 mAb 37.51 (2 g͞ml). Where indicated (ϩ), biotinylated anti-CTLA-4 mAb UC10-4F10-11 (10 g͞ml) and avidin (20 g͞ml) were added to the cultures. At the end of the incubation period the cells were harvested and washed once in PBS. Cells were resuspended in 0.1% Nonidet P-40, 0.1% sodium citrate, and 50 g͞ml propidium iodide and analyzed by flow cytometry. Events were analyzed for propidium iodide fluorescence and markers were set corresponding to subdiploid, G0͞G1, and S͞G2 quantities. All cells were analyzed for a fixed time period at a constant flow rate to account for differences in cell number at the end of the stimulation period (23).
FIG. 5. CTLA-4-induced death of preactivated CD4 ϩ T cells is not inhibited by anti-Fas antibody. Purified CD4 ϩ cell blasts, prepared as outlined in the legend to Fig. 3 , were recultured for 24 h in biotin-free RPCCM medium containing Con A (2.5 g͞ml) and anti CD28 mAb 37.51 (2 g͞ml), in the presence of biotinylated anti-CTLA-4 mAb UC10-4F10-11 (10 g͞ml) and͞or avidin (20 g͞ml). In the experimental group depicted in the lower right graph, T cells were preincubated with anti-Fas mAb Jo2 (5 g͞ml). At the end of the incubation period the cells were harvested and washed once in PBS. Cells were resuspended in 0.1% Nonidet P-40, 0.1% sodium citrate, and 50 g͞ml propidium iodide and analyzed by flow cytometry for propidium iodide fluorescence. Soluble Jo2 mAb was functional, because it was able to inhibit apoptosis of activated CD4 ϩ T cells induced by immobilized Jo2 mAb. In a representative control experiment, numbers of apoptotic cells were as follows: no antibody, 17.1%; soluble Jo2 mAb (5 g͞ml), 25.4%; immunobilized Jo2 mAb (1 g͞ml), 50.2%; soluble and immobilized Jo2 mAb, 21.6%.
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Proc. Natl. Acad. Sci. USA 95 (1998) 10087 lymphocytes from these mice. In addition, the results of our study raise the possibility that crosslinking of CTLA-4 in vivo, e.g., by infusion of a biotinylated anti-CTLA-4 mAb followed by avidin, may be a possible strategy for the treatment of autoimmune diseases that are otherwise refractory to therapy. Moreover, that CTLA-4 crosslinking can induce death of activated T cells from lpr mice raises the intriguing possibility that such a regimen might be used to treat children suffering from a lymphoproliferative syndrome resulting from Fas deficiency (41, 42) . These possibilities will need to be explored.
